Sign In
Buy LYEL
$12.57
-2.32 (-15.58%)
At Close: Jun 03, 2026
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
04:05pm, Wednesday, 07'th Aug 2024
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies f
3 Biotech Stocks to Sell in August Before They Crash & Burn
08:00am, Tuesday, 06'th Aug 2024
For investors, one of the most attractive aspects of biotech stocks is their ability to increase in value in a short period of time quickly. After all, it only takes one major breakthrough in clinical
SOUTH SAN FRANCISCO, Calif., June 26, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies f
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
04:05pm, Monday, 03'rd Jun 2024
SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies f
Lyell Immunopharma to Participate in BofA Securities Health Care Conference
04:05pm, Tuesday, 07'th May 2024
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies fo
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
08:00am, Monday, 06'th May 2024
SOUTH SAN FRANCISCO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies fo
Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts
06:25pm, Tuesday, 16'th Apr 2024
Lyell Immunopharma, Inc.'s stock price has risen over 20% YTD and over 45% in the past 12 months. The company focuses on T-cell therapies for solid tumors and has two clinical-stage assets. Lyell has
Lyell Immunopharma (LYEL) Is Up 28.45% in One Week: What You Should Know
01:01pm, Thursday, 07'th Mar 2024
Does Lyell Immunopharma (LYEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
04:30pm, Tuesday, 05'th Mar 2024
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
04:05pm, Wednesday, 28'th Feb 2024
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies f
Lyell Immunopharma Announces Participation in March Investor Conferences
04:05pm, Monday, 26'th Feb 2024
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies f
Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference
04:05pm, Wednesday, 03'rd Jan 2024
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies f
Lyell Immunopharma: Potential Solid Tumor Targeting With CAR-T And TIL
02:23pm, Friday, 10'th Nov 2023
Lyell Immunopharma results from a phase 1 study using LYL797 for the treatment of relapsed/refractory NSCLC and TNBC patients with ROR1 expression expected in the 1st half of 2024. Results from phase
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
04:05pm, Thursday, 09'th Nov 2023
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies f
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
04:05pm, Tuesday, 07'th Nov 2023
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T‑cell reprogramming company advancing a diverse pipeline of cell therapies
